Dendreon Corp., of Seattle, named Christopher Lockett senior director of government affairs, and promoted Mark Frohlich to vice president of clinical affairs

AtheroGenics Inc., of Atlanta, appointed Walker Anderson Long vice president of clinical research

Celsion Corp., of Columbia, Md., appointed William Hahne vice president clinical development and medical affairs, and Christopher Black executive director, preclinical research...and Jennifer Cook Williams to vice president, investor relations

UCB, of Brussels, Belgium, appointed Bill Robinson and Bob Trainor as new members of the company's executive committee...Vivus Inc., of Mountain View, Calif., appointed Wesley Day vice president of clinical development

NPS Pharmaceuticals, of Salt Lake City, appointed Anthony Coles president and chief operating officer...Peregrine Pharmaceuticals Inc., of Tustin, Calif., appointed Alfred Prince, Peter Barry and Arnold Monto to its scientific resource board...Pharmos Corp., of Iselin, N.J., appointed Alan Rubino president and chief operating officer

Cardium Therapeutics Inc., of San Diego, appointed Dennis Mulroy chief financial officer, Robert Engler chief medical adviser, Patricia Novak vice president of program development, Ted Williams vice president of manufacturing and technical operations, Jennifer Spinella vice president of regulatory affairs and Anthony Andrasfay vice president of clinical operations

and Eric Emery vice president, manufacturing, and as the Minnesota site head...Tranzyme Pharma, of Research Triangle Park, N.C., appointed Gordana Kosutic vice president of clinical and regulatory affairs

Avidia Inc., of Mountain View, Calif., appointed Patricia Walicke vice president of clinical and regulatory affairs and Richard Powers independent director of its board

Tanox Inc., of Houston, appointed Linda Paradiso vice president of clinical operations and regulatory affairs

plc, of London, appointed Anthony Clarke vice president of clinical development at Amarin Neuroscience

VaxGen Inc., of Brisbane, Calif., appointed Eve Slater and Kevin Reilly to its board...ViaCell Inc., of Boston, appointed Paul Blake and James Sigler to its board...XOMA Ltd., of Berkeley, Calif., appointed Alan Solinger vice president of clinical immunology

Caraco Pharmaceutical Laboratories Ltd., of Detroit, appointed John Crissman and Madhava Reddy to its board...Haemonetics Corp., of Braintree, Mass., appointed Richard Meelia and Ronald Merriman to its board...Intrac Inc., of New York, and its subsidiary Innovative Drug Delivery Systems, appointed William Peters to its board

NicOx SA, of Sophia-Antipolis, France, appointed Maarten Beekman vice president of clinical development, Ali Raza and Stefano Bionid director of the research laboratories, and promoted Ennio Ongini to vice president of research...Revance Therapeutics, of Mountain View, Calif., appointed Mary Spellman senior vice president of clinical development, Jane Moffitt senior vice president of regulatory affairs, and Bobby Purkait senior vice president of R&D and operations

and Michael Varney vice president, small-molecule drug discovery...MacroGenics Inc., of Rockville, Md., appointed Nelson Campbell and Ronald Wilder to its senior management team, and promoted Ezio Bonvini to vice president of research, and Joseph Panigot to vice president of legal affairs...NeoRx Corp., of Seattle, appointed David Karlin senior vice president of clinical development and regulatory affairs

Alfacell Corp., of Bloomfield, N.J., appointed Jacob Maizel and Susanna Rybak to its scientific advisory board...CuraGen Corp., of New Haven, Conn., appointed Michael Astrue and Frank Armstrong to its board...MacroPore Biosurgery Inc., of San Diego, appointed Alex Milstein vice president of clinical research, and Kenneth Chien scientific adviser

Immusol Inc., of San Diego, appointed Barry Simon vice president of clinical and regulatory affairs, and Zhu Shen director of business development

TyRx Pharma Inc., of Monmouth Junction, N.J., appointed William McJames vice president of product development, and Mason Diamond vice president of clinical and regulatory affairs

Jonathan Rachman vice president of clinical development for the diabetes/obesity team...and Karsten Witt senior medical officer for drug safety

Halozyme Therapeutics Inc., of San Diego, appointed Richard Yocum vice president of clinical development and medical affairs